Aytu BioScience, Inc. Securities Litigation

If you purchased a significant amount of shares of Aytu BioScience, Inc. (NASDAQ: AYTU), you have certain options. Investors should contact us.

 

Lawsuit Overview

Defendant:Aytu BioScience, Inc.
Date Filed:November 26th, 2019
Sector:Health Care
Industry:Major Pharmaceuticals

According to the Complaint, Aytu BioScience, Inc. is a commercial-stage specialty pharmaceutical company focused on commercializing novel products that address significant patient needs.

This action stems from Defendants' dissemination of a proxy statement filed with the United States Securities and Exchange Commission on November 21, 2019. The Complaint alleges that the Proxy Statement omits material information, which renders the Proxy Statement false and misleading.

Sign up for free to create a personalized portfolio with tracking and e-mail alerts for Aytu BioScience, Inc.

 
First Identified Complaint

Adam Franchi, et al. v. Aytu BioScience, Inc., et al.

Date Filed:November 26th, 2019
Class Period Start:November 21st, 2019
Class Period End:November 26th, 2019
First Identified Complaint Filings
#Document TitleFiling Date